Is It Safe to Take Semaglutide or Other GLP-1s While Breastfeeding?

The short version first: most drug manufacturers and many clinicians advise against using GLP-1 medications like semaglutide while breastfeeding, mainly because long-term safety data in nursing infants is still limited. At the same time, early research measuring the drug in human milk has been reassuring. Here is what the current evidence says, and the questions worth raising with your own clinician.

The short answer

There is no clean yes. Manufacturers of semaglutide products such as Ozempic and Wegovy generally recommend against use during breastfeeding, and some specialists take a firm cautious stance because there is little direct data on how these drugs affect newborns. Other researchers point to newer studies suggesting the amount that reaches breast milk is extremely low. Both things can be true at once, which is why this remains a personal decision made with a clinician who knows your history rather than a rule that fits everyone.

What the milk-transfer research shows

The most cited direct evidence comes from a 2024 study that measured semaglutide in the breast milk of a small group of women using sensitive laboratory methods. Researchers found the drug at undetectable or extremely low levels, and estimated that only a tiny fraction of the maternal dose could reach an infant through milk, well below thresholds usually considered concerning. Follow-up analyses reported through 2025 described similar results, with no clear signal that milk composition or infant growth was affected. These studies are small and short, so they are a useful starting point rather than a final verdict. They tell us about drug levels in milk, not about long-term outcomes in the children who nurse.

Why official guidance stays cautious

Even with encouraging milk data, prescribing information and several experts still err on the side of caution. The core reason is simple: we do not yet have large, long-term studies following babies exposed to GLP-1s through breast milk. Because semaglutide is a large peptide molecule, many experts expect it to be poorly absorbed in an infant's gut, but that is a reasonable inference rather than a proven fact. Interest in postpartum use has grown sharply in the last few years, and one center that advises on medication safety reported a large jump in calls from nursing mothers asking about these drugs. That surge in demand is exactly why careful, individualized guidance matters instead of a blanket answer.

Timing, milk supply, and rapid weight loss

A separate issue is milk supply. The medication itself does not appear to reduce supply directly, but the fast weight loss and reduced appetite that come with GLP-1s can. Sharp calorie cuts and dehydration can lower supply, so if breastfeeding is going well, slow and steady changes tend to be gentler on lactation. Some clinicians suggest waiting until supply is well established before considering any weight medication, and building meals and fluids around the days you feel most nauseated.

This is also a moment where pregnancy planning overlaps. Manufacturers advise stopping these medications well before trying to conceive, and if you might become pregnant again, contraception is worth a direct conversation, since GLP-1s can complicate how the pill is absorbed. If that applies to you, our explainer on GLP-1s and birth control walks through what the reports actually say.

What women may want to track

If you and your clinician are weighing this decision, keeping a simple record helps. Noting your dose timing, any changes in milk supply, your appetite and hydration, and your baby's feeding and weight patterns gives your care team real data to work with instead of guesswork. You can also track how your cycle returns postpartum, since GLP-1s can shift menstrual patterns once your period comes back. A cycle-aware tool like PepFem that lets you log doses and symptoms in one place can make those conversations with your provider clearer and less stressful.